Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Amortizatization of Intangibles (2019 - 2025)

Crinetics Pharmaceuticals has reported Amortizatization of Intangibles over the past 7 years, most recently at $2.7 million for Q4 2025.

  • Quarterly results put Amortizatization of Intangibles at $2.7 million for Q4 2025, down 78.38% from a year ago — trailing twelve months through Dec 2025 was $15.4 million (up 3.31% YoY), and the annual figure for FY2025 was $15.4 million, up 3.31%.
  • Amortizatization of Intangibles for Q4 2025 was $2.7 million at Crinetics Pharmaceuticals, down from $3.6 million in the prior quarter.
  • Over the last five years, Amortizatization of Intangibles for CRNX hit a ceiling of $12.6 million in Q4 2024 and a floor of -$5.0 million in Q3 2024.
  • Median Amortizatization of Intangibles over the past 5 years was $440500.0 (2022), compared with a mean of $1.6 million.
  • Biggest five-year swings in Amortizatization of Intangibles: tumbled 520.8% in 2023 and later soared 956.33% in 2024.
  • Crinetics Pharmaceuticals' Amortizatization of Intangibles stood at -$186000.0 in 2021, then skyrocketed by 288.71% to $351000.0 in 2022, then tumbled by 520.8% to -$1.5 million in 2023, then soared by 956.33% to $12.6 million in 2024, then plummeted by 78.38% to $2.7 million in 2025.
  • The last three reported values for Amortizatization of Intangibles were $2.7 million (Q4 2025), $3.6 million (Q3 2025), and $4.7 million (Q2 2025) per Business Quant data.